Zinc containing compositions for anti-viral use
OwnerJeffrey B. Smithinventor
Life of this patent
Estimating the term…
Abstract
One aspect of the invention relates to anti-viral composition containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients such as at least one analgesic) at least one hydrocarbyl containing compound, and water. Another aspect of the invention relates to a method of treating lesionous symptoms of a viral infection involving applying an effective amount of the zinc containing anti-viral composition to the lesions.
Claims20
A method of treating lesionous symptoms of a viral infection, comprising:
- applying an effective amount of a zinc containing composition to the lesions, the zinc containing composition comprising about 0.005% by weight or more and about 20% by weight or less of at least one zinc compound, about 0.001% by weight or more and about 20% by weight or less of at least one phenolic antioxidant selected from the group consisting of a butylated hydroxytoluene, 2(3)-tert-butyl-4-methoxyphenol, 2,6-di-tert-butyl-4-cumylphenol, 2,6-di-tert-butyl-4-nonylphenol, 2,6-dicumylphenol, 2,6-di-tert-butyl-4-isooctylphenol, and 4,4′-methylene-bis(2,6-di-tert-butylphenol), and a pharmaceutically acceptable adjuvant.
A method for the topical treatment of herpes infections in humans, comprising applying to an area of skin or mucous membrane infected with herpes an effective amount of a zinc containing composition comprising about 0.01% by weight or more and about 10% by weight or less of at least one zinc salt, about 0.005% by weight or more and about 10% by weight or less of at least one phenolic antioxidant selected from the group consisting of a butylated hydroxytoluene, 2(3)-tert-butyl-4-methoxyphenol, 2,6-di-tert-butyl-4-cumylphenol, 2,6-di-tert-butyl-4-nonylphenol, 2,6-dicumylphenol, 2,6-di-tert-butyl-4-isooctylphenol, and 4,4′-methylene-bis(2,6-di-tert-butylphenol), and a pharmaceutically acceptable adjuvant.
A method of treating lesionous symptoms of a viral infection, comprising:
- applying an effective amount of a zinc containing composition to the lesions, the zinc containing composition comprising about 0.005% by weight or more and about 20% by weight or less of at least one zinc compound, about 0.001% by weight or more and about 20% by weight or less of at least one butylated hydroxytoluene, and a pharmaceutically acceptable adjuvant;
- and
- adhering to at least one of a low arginine diet and a high lysine diet.
A method for the topical treatment of herpes infections in humans, comprising:
- applying to an area of skin or mucous membrane infected with herpes an effective amount of a zinc containing composition comprising about 0.01% by weight or more and about 10% by weight or less of at least one zinc salt, about 0.005% by weight or more and about 10% by weight or less of at least one butylated hydroxytoluene, and a pharmaceutically acceptable adjuvant;
- and
- adhering to at least one of a low arginine diet and a high lysine diet.
A method of treating symptoms of a viral infection, comprising:
- applying an effective amount of a zinc containing composition to the lesions, the zinc containing composition comprising about 0.005% by weight or more and about 20% by weight or less of at least one zinc compound, the zinc compound comprises at least one selected from the group consisting of zinc, zinc chloride, zinc acetate, zinc citrate, zinc sudoxicam, zinc sulfate, zinc nitrate, zinc carbonate, zinc tartrate, zinc maleate, zinc lactate, zinc aminoacetate, zinc aspartate, zinc glutamate, zinc propionate, zinc oleate, zinc benzoate, zinc butyrate, zinc formate, zinc glycerate, zinc glycolate, zinc oxide, zinc ethylenediamine tetraacetate, zinc pentosan polysulfate, zinc oxyacetate, and hydrates thereof, about 0.001% by weight or more and about 20% by weight or less of at least one phenolic antioxidant selected from the group consisting of a butylated hydroxytoluene, 2(3)-tert-butyl-4-methoxyphenol, 2,6-di-tert-butyl-4-cumylphenol, 2,6-di-tert-butyl-nonylphenol, 2,6-dicumylphenol, 2,6-di-tert-butyl-4-isooctylphenol, and 4,4′-methylene-bis(2,6-di-tert-butylphenol), and a pharmaceutically acceptable adjuvant.
Dependencies are inferred from the claim text.